Pathophysiology & Presentation - The Synovial Showdown
- Pathogenesis: Genetic susceptibility (HLA-DR4) + environmental trigger → T-cell activation.
- B-cells produce Rheumatoid Factor (RF) & highly specific Anti-Citrullinated Protein Antibodies (ACPA).
- Synovial inflammation & proliferation → pannus formation (destructive granulation tissue).
- Pannus erodes articular cartilage and bone.
- Key cytokines: TNF-α, IL-1, IL-6.
- Clinical Presentation: Insidious, symmetric, inflammatory polyarthritis.
- Morning stiffness > 1 hour, improves with activity.
- Affects small joints: MCPs, PIPs, wrists, MTPs.
- Systemic symptoms: low-grade fever, fatigue, weight loss.
⭐ Exam Favorite: RA characteristically spares the distal interphalangeal (DIP) joints, a key feature distinguishing it from osteoarthritis.

Diagnosis & Serology - Cracking the RA Code
-
ACR/EULAR 2010 Criteria: Score ≥6/10 for definitive RA diagnosis.
- Joints (0-5): Based on number & size of joints.
- Serology (0-3): RF & anti-CCP levels.
- Acute Phase Reactants (0-1): ↑ESR or ↑CRP.
- Duration (0-1): Symptoms ≥6 weeks.
-
Key Antibodies:
- Anti-CCP (ACPA): Most specific marker (~95%); predicts erosive disease.
- Rheumatoid Factor (RF): Sensitive but not specific.
-
Other Labs:
- Synovial Fluid: Inflammatory (WBC 2,000-75,000/μL, >50% PMNs).
-
Imaging (X-ray):
- Early: Soft tissue swelling, periarticular osteopenia.
- Late: Joint space narrowing, marginal erosions.
⭐ High-Yield: Anti-CCP antibodies may be positive years before clinical symptoms manifest, identifying individuals at high risk for developing RA.

Extra-Articular Manifestations - Systemic Synovial Strike
- General: Fever, weight loss, fatigue, myalgias.
- Dermatologic:
- Rheumatoid nodules: Firm, subcutaneous on extensor surfaces (e.g., olecranon, occiput).
- Rheumatoid vasculitis: Palpable purpura, skin ulcers.
- Pulmonary:
- Pleuritis, pleural effusion (exudative, low glucose).
- Interstitial Lung Disease (ILD).
- Caplan Syndrome: Pneumoconiosis + rheumatoid nodules in lungs.
- Cardiovascular:
- Pericarditis is most common.
- Accelerated atherosclerosis, ↑ risk of MI.
- Ocular: Keratoconjunctivitis sicca, scleritis.
- Hematologic: Anemia of chronic disease, thrombocytosis.
⭐ Felty Syndrome: A severe complication characterized by the triad of long-standing RA, splenomegaly, and neutropenia (<2,000/mm³), leading to recurrent infections.

RA Management - Taming the Flame
- Goal: Control synovitis, prevent joint damage, preserve function. Bridge with NSAIDs/corticosteroids for flares.
- DMARDs:
- csDMARDs: Methotrexate, Sulfasalazine, Hydroxychloroquine (retinal toxicity), Leflunomide.
- bDMARDs (TNF-α inhibitors): Etanercept, Infliximab. ↑ risk of infection.
- tsDMARDs (JAK inhibitors): Tofacitinib. ↑ risk of thrombosis, shingles.

⭐ Before initiating biologic DMARDs (e.g., TNF-α inhibitors), screening for latent Tuberculosis (PPD/IGRA) and viral hepatitis (B & C) is mandatory.
High‑Yield Points - ⚡ Biggest Takeaways
- Symmetrical, inflammatory polyarthritis primarily affecting small joints (MCP, PIP) while sparing the DIP joints.
- Hallmark is morning stiffness lasting > 60 minutes that improves with activity.
- Key serological markers include Rheumatoid Factor (RF) and the more specific anti-citrullinated peptide (anti-CCP) antibodies.
- Characteristic deformities include ulnar deviation, swan-neck, and boutonnière deformities.
- Methotrexate is the cornerstone first-line DMARD for management.
- Associated with C1-C2 subluxation (atlantoaxial instability) and systemic features like rheumatoid nodules.
Continue reading on Oncourse
Sign up for free to access the full lesson, plus unlimited questions, flashcards, AI-powered notes, and more.
CONTINUE READING — FREEor get the app